Extracorporeal Adsorption Therapy: A Method to Improve Targeted Radiation Delivered by Radiometal-Labeled Monoclonal Antibodies
| Autor: | Yukang Lin, John M. Pagel, D. Scott Wilbur, Oliver W. Press, Joseph G. Rajendran, Darrell R. Fisher, Lawrence D. Durack, Ajay K. Gopal, Rune Nilsson, Bengt Sandberg, Eneida R. Nemecek, Damian J. Green |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Cancer Research Pathology medicine.medical_specialty Biodistribution Immunoconjugates Radioimmunoconjugate medicine.drug_class medicine.medical_treatment Lutetium Monoclonal antibody Extracorporeal Antibodies Monoclonal Murine-Derived Drug Delivery Systems medicine Animals Radiology Nuclear Medicine and imaging Radiometry Radioisotopes Pharmacology business.industry Antibodies Monoclonal General Medicine medicine.disease Lymphoma medicine.anatomical_structure Oncology Radioimmunotherapy Monoclonal Macaca Bone marrow Rituximab business Nuclear medicine |
| Zdroj: | Cancer Biotherapy and Radiopharmaceuticals. 23:181-191 |
| ISSN: | 1557-8852 1084-9785 |
| DOI: | 10.1089/cbr.2007.0433 |
| Popis: | Radiolabeled anti-CD20 antibodies have demonstrated impressive efficacy in the treatment of relapsed non-Hodgkin's lymphoma. However, the amount of radiation that can be delivered to eradicate the malignancy is limited by toxicity to normal organs. We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model.ECAT was applied with an avidin-agarose column 24 hours after an injection of (111)In- or (177)Lu-DOTA-biotin-rituximab (anti-CD20 antibody) to normal macaques. Two (2) animals were studied in initial blood clearance studies, and 6 additional animals were evaluated in subsequent detailed biodistribution experiments. After the injection of (111)In- or (177)Lu-antibody, 3 animals underwent ECAT circulating one volume/hour while 3 served as controls. Serial blood, marrow, and lymph node samples, gamma-camera images, and necropsy tissues were obtained to estimate radiation-absorbed doses in organs of interest.Optimal blood clearance (98%) was achieved by performing ECAT at a flow rate of one blood volume/hour. Radiation doses to normal organs were reduced with ECAT in kidney (49% +/- 12%), liver (42% +/- 10%), lungs (60% +/- 6%), total body (51% +/- 16%), marrow (50% +/- 15%), spleen (38% +/- 10%), and lymph nodes (19% +/- 3%). Despite dose reduction in both target and nontarget tissues, therapeutic ratios were significantly higher in animals treated with ECAT (20% higher for spleen:kidney and 60% for lymph node:kidney), compared to controls.ECAT is a safe, feasible, and effective method to remove unbound radioimmunoconjugates from the bloodstream and reduce the nonspecific radiation exposure of normal tissues. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|